Clinical Trials Related to Eli Lilly and Company

Related studies linked through entity extraction aliases.

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Status: COMPLETED
Phase: N/A

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Status: COMPLETED
Phase: PHASE1

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Status: COMPLETED
Phase: PHASE1

Study of Abemaciclib in Dedifferentiated Liposarcoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Study of Galcanezumab in Healthy Participants.

Status: COMPLETED
Phase: PHASE1

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Status: COMPLETED
Phase: PHASE1

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Status: WITHDRAWN
Phase: PHASE2

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Status: COMPLETED
Phase: PHASE1

A Study of LY3023414 Formulations and the Effect of Food

Status: COMPLETED
Phase: PHASE1

A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes

Status: COMPLETED
Phase: PHASE1

A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes

Status: TERMINATED
Phase: PHASE1

A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

Status: COMPLETED
Phase: PHASE3

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Status: COMPLETED
Phase: PHASE2

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Status: APPROVED_FOR_MARKETING
Phase: N/A

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Status: COMPLETED
Phase: NA

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Status: COMPLETED
Phase: PHASE1

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

Status: TERMINATED
Phase: PHASE2

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Status: COMPLETED
Phase: PHASE1

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Status: TERMINATED
Phase: PHASE1

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Status: COMPLETED
Phase: PHASE1